
    
      The IMC-C103C-101 Phase 1/2 study will be evaluated in patients with metastatic/unresectable
      tumors which include select Advanced Solid Tumors and will be conducted in two phases.

        1. To identify the MTD and/or RP2D of IMC-C103C as a single agent administered Q1W (Arm A1)
           and administered Q1W in combination with Q3W atezolizumab (Arm A2).

        2. To assess the preliminary anti-tumor activity of IMC C103C in one or more selected
           indications, as a single agent administered Q1W (Arm B1) and administered Q1W in
           combination with Q3W atezolizumab (Arm B2).
    
  